Advertisement

Topics

Labopharm Company Profile

12:29 EST 20th November 2017 | BioPortfolio

We are an emerging leader in optimizing the performance of existing small molecule drugs using our proprietary controlled-release technologies. Our lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and we have a robust pipeline of follow-on products in both pre-clinical and clinical development. Our vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize our own products.

Location

480 Armand-Frappier Blvd
Laval
Québec
H7V 4B4
Canada

Contact

Phone: (450) 686-1017 or 1 888 686-1017
Fax: (450) 686-9141
Email: info@labopharm.com


News Articles [2 Associated News Articles listed on BioPortfolio]

Angelini Labopharm, PTV News: Apr 30, 2010

Joint Venture agreed to market Oleptro in the US

News Headlines, PTV News: Apr 30, 2010

A look at today's forthcoming news stories:Dendreon's Provenge, a first of a kind prostate cancer treatment, wins FDA approval; a raft of Q1 results came out this week, painting a positive financial p...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions

To determine whether the test product, Labopharm Tramadol HCl Once-A-Day (OAD) 200 mg film-coated tablets, and the reference product, Labopharm Tramadol HCl OAD 200 mg uncoated tablets, ar...

A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers

The purposes of this study were: - To evaluate the plasma pharmacokinetic profile of tramadol and its principal metabolite, the O-desmethyltramadol, after a single oral administra...

Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg

The main purpose of this study is to compare the pharmacokinetic profile to establish the better controlled liberation of the test product (Tramadol HCL OAD tablets of 200 mg, Labopharm) a...

Companies [4 Associated Companies listed on BioPortfolio]

Angelini Labopharm

For the purpose of marketing OLEPTRO(TM) in the United States, Angelini and Labopharm established the joint venture Angelini Labopharm, which is equally owned by both companies. This partnership leve...

Angelini Labopharm, LLC

For the purpose of marketing OLEPTRO(TM) in the United States, Gruppo Angelini and Labopharm established the joint venture Angelini Labopharm, which is equally owned by affiliates of both companies. T...

Labopharm Inc.

Labopharm

We are an emerging leader in optimizing the performance of existing small molecule drugs using our proprietary controlled-release technologies. Our lead product, a unique once-daily formulation of tra...

More Information about "Labopharm" on BioPortfolio

We have published hundreds of Labopharm news stories on BioPortfolio along with dozens of Labopharm Clinical Trials and PubMed Articles about Labopharm for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Labopharm Companies in our database. You can also find out about relevant Labopharm Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record